Trials / Completed
CompletedNCT00292071
Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)
A Multicenter, Open, Sequential Dose-Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 2 Separate Doses of Caspofungin Acetate in Children Between the Ages of 3 to 24 Months With New Onset Fever and Neutropenia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 3 Months – 24 Months
- Healthy volunteers
- Not accepted
Summary
This is an open-label study of MK0991 in children between 3 to 24 months of age with new onset fever and neutropenia. The purpose of the study is to investigate plasma drug levels of caspofungin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | caspofungin acetate | (50 mg/m²/day and 70 mg/m²/day) Caspofungin will be given for a minimum of 4 days (or at least 2 separate days of 7-point plasma sampling). Patients will be administered caspofungin for a maximum of 28 days. |
Timeline
- Start date
- 2004-05-01
- Primary completion
- 2006-07-01
- Completion
- 2006-07-01
- First posted
- 2006-02-15
- Last updated
- 2017-02-23
Source: ClinicalTrials.gov record NCT00292071. Inclusion in this directory is not an endorsement.